Author

Jodi Marie Weidler

Observed names: J Weidler, J. M. Weidler, J. Weidler, J.M. Weidler, JODI WEIDLER, Jodi M Weidler, Jodi M. Weidler, Jodi Weidler, Jodi M. Weidler, Weidler, Jodi

Institution: Cepheid (United States)

Observed institutions: Medical University of Lublin, Pennsylvania State University, Mayo Clinic, Danaher (United States), LabCorp (United States), Lebanon VA Medical Center, Greater Poland Cancer Center, Medical University of Lodz, Lublin Oncology Center, Diazyme (United States), Mayo Clinic in Florida, Wojskowy Instytut Medyczny, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Foundation Medicine (United States), Cepheid (United States), Gdańsk Medical University, Medical University of Vienna, Penn State Milton S. Hershey Medical Center

OpenAlex ID: A5043601605

Quantitation of p95HER2 in Paraffin Sections by Using a p95-Specific Antibody and Correlation with Outcome in a Cohort of Trastuzumab-Treated Breast Cancer Patients

2010 · Jeff Sperinde, Xueguang Jin, et al. · Clinical Cancer Research · 177

PDF

HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer

2013 · Allan Lipton, Laurie Goodman, et al. · Breast Cancer Research and Treatment · 77

PDF

Rate of Viral Evolution and Risk of Losing Future Drug Options in Heavily Pretreated, HIV-Infected Patients Who Continue to Receive a Stable, Partially Suppressive Treatment Regimen

2006 · H. Hatano, P. Hunt, et al. · Clinical Infectious Diseases · 72

Relationship Between HIV Coreceptor Tropism and Disease Progression in Persons With Untreated Chronic HIV Infection

2009 · Matthew Bidwell Goetz, Robert Leduc, et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 55

Comparison of central laboratory assessments of ER, PR, HER2, and Ki67 by IHC/FISH and the corresponding mRNAs (ESR1, PGR, ERBB2, and MKi67) by RT-qPCR on an automated, broadly deployed diagnostic platform

2018 · Natalie C. Wu, Wendy Wong, et al. · Breast Cancer Research and Treatment · 54

PDF

Prevalence of Primary HIV‐1 Drug Resistance among Recently Infected Adolescents: A Multicenter Adolescent Medicine Trials Network for HIV/AIDS Interventions Study

2006 · Rolando M. Viani, Ligia Peralta, et al. · The Journal of Infectious Diseases · 53

Novel Method To Assess Antiretroviral Target Trough Concentrations UsingIn VitroSusceptibility Data

2012 · Edward P. Acosta, Kay L. Limoli, et al. · Antimicrobial Agents and Chemotherapy · 52

Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization‐positive patients with metastatic breast cancer treated with trastuzumab

2010 · Allan Lipton, Wolfgang J. Köstler, et al. · Cancer · 52

PDF

Analytical Validation of a Highly Quantitative, Sensitive, Accurate, and Reproducible Assay (HERmark®) for the Measurement of HER2 Total Protein and HER2 Homodimers in FFPE Breast Cancer Tumor Specimens

2010 · Jeffrey S. Larson, Laurie J. Goodman, et al. · Pathology Research International · 51

PDF

Greater CD4 T-cell gains after one year of antiretroviral therapy are associated with lower HIV-1 pol replication capacity

2006 · Jason D Barbour, Frederick M Hecht, et al. · AIDS · 48

Quantitative measurement of HER2 expression in breast cancers: comparison with ‘real-world’ routine HER2 testing in a multicenter Collaborative Biomarker Study and correlation with overall survival

2015 · Denise A Yardley, Peter A Kaufman, et al. · Breast Cancer Research · 47

PDF

Comparison of Central HER2 Testing With Quantitative Total HER2 Expression and HER2 Homodimer Measurements Using a Novel Proximity-Based Assay

2010 · Weidong Huang, Monica Reinholz, et al. · American Journal of Clinical Pathology · 46

PDF

High p95HER2/HER2 Ratio Associated With Poor Outcome in Trastuzumab-Treated HER2-Positive Metastatic Breast Cancer NCCTG N0337 and NCCTG 98-32-52 (Alliance)

2018 · Saranya Chumsri, Jeff Sperinde, et al. · Clinical Cancer Research · 43

Prolonged Response to Trastuzumab in a Patient With HER2-Nonamplified Breast Cancer With Elevated HER2 Dimerization Harboring anERBB2S310F Mutation

2015 · Saranya Chumsri, Jodi Weidler, et al. · Journal of the National Comprehensive Cancer Network · 41

PDF

Quantitative Measurements of Tumoral p95HER2 Protein Expression in Metastatic Breast Cancer Patients Treated with Trastuzumab: Independent Validation of the p95HER2 Clinical Cutoff

2014 · Renata Duchnowska, Jeff Sperinde, et al. · Clinical Cancer Research · 39

Correlation Between Quantitative HER-2 Protein Expression and Risk for Brain Metastases in HER-2+ Advanced Breast Cancer Patients Receiving Trastuzumab-Containing Therapy

2012 · Renata Duchnowska, Wojciech Biernat, et al. · The Oncologist · 37

Quantitative HER2 and p95HER2 levels in primary breast cancers and matched brain metastases

2015 · R. Duchnowska, J. Sperinde, et al. · Neuro-Oncology · 34

Identification of a subpopulation of metastatic breast cancer patients with very high HER2 expression levels and possible resistance to trastuzumab

2011 · M. Bates, J. Sperinde, et al. · Annals of Oncology · 30

Multi-Institutional Study of Pathologist Reading of the Programmed Cell Death Ligand-1 Combined Positive Score Immunohistochemistry Assay for Gastric or Gastroesophageal Junction Cancer

2023 · Aileen I. Fernandez, Charles J. Robbins, et al. · Modern Pathology · 28

PDF

Correlation of HER2, p95HER2 and HER3 Expression and Treatment Outcome of Lapatinib plus Capecitabine in her2-Positive Metastatic Breast Cancer

2012 · Sae-Won Han, Yongjun Cha, et al. · PLoS ONE · 28

PDF

High concordance of a closed-system, RT-qPCR breast cancer assay for HER2 mRNA, compared to clinically determined immunohistochemistry, fluorescence in situ hybridization, and quantitative immunofluorescence

2017 · Brad E Wasserman, Daniel E Carvajal-Hausdorf, et al. · Laboratory Investigation · 26

PDF

ESR1, PGR, ERBB2, and MKi67 mRNA expression in postmenopausal women with hormone receptor-positive early breast cancer: results from ABCSG Trial 6

2021 · M. Filipits, M. Rudas, et al. · ESMO Open · 25

Very high quantitative tumor HER2 content and outcome in early breast cancer

2011 · H. Joensuu, J. Sperinde, et al. · Annals of Oncology · 25

Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanoma

2019 · Swati Gupta, Leena McCann, et al. · Journal for ImmunoTherapy of Cancer · 23

p95HER2 Methionine 611 Carboxy-Terminal Fragment Is Predictive of Trastuzumab Adjuvant Treatment Benefit in the FinHer Trial

2018 · Jeff Sperinde, Weidong Huang, et al. · Clinical Cancer Research · 23

Works count: 97

Citation count: 1,359

H-index: 23

I10-index: 34